**References**

Variations 1 and 2:

Variation 3:

Variation 4:

**Afatinib (NSCLC Regimen)**

**Use** Lung cancer, non-small cell

**Regimen**
Afatinib: Oral: 40 mg once daily days 1 to 21
[total dose/cycle = 840 mg]
Repeat cycle every 21 days until disease progression or unacceptable toxicity

**References**

**AIM (Soft Tissue Sarcoma)**

**Index Terms**
- Doxorubicin-Ifosfamide (Soft Tissue Sarcoma); Ifosfamide-Doxorubicin (Soft Tissue Sarcoma)

**Use** Soft tissue sarcoma

**Regimen**
NOTE: Mesna uroprotection should be administered before and 4 and 8 hours after ifosfamide days 1 to 4.
Ifosfamide: IV: 1,500 mg/m²/day over 2 hours days 1 to 4
[total dose/cycle = 6,000 mg/m²]
Doxorubicin: IV: 20 mg/m²/day continuous infusion days 1, 2, and 3
[total dose/cycle = 60 mg/m²]
Filgrastim: SubQ: 5 mcg/kg/day for 10 days, starting 24 hours after last dose of mesna
[total dose/cycle = 50 mcg/kg]
Repeat cycle every 21 days for a total of 4 cycles for localized disease and 6 cycles for metastatic disease

**References**

◆ Aldesleukin-Interferon Alfa-2 (RCC) see Interleukin 2-Interferon Alfa-2 (RCC) on page 2018
◆ AlinC 14 see PVA (POG 8602) on page 2069
◆ AP (Endometrial) see Cisplatin-Doxorubicin (Endometrial) on page 1892
◆ Arsenic Trioxide-ATRA (APL) see Tretinoin-Arsenic Trioxide (APL) on page 2095
◆ Arsenic Trioxide-ATRA-Daunorubicin-Cytarabine (APL) see Tretinoin-Daunorubicin-Cytarabine Induction, Consolidation, Maintenance (APL) on page 2097